Pliant Therapeutics, Inc.

The company is a clinical-stage biopharmaceutical company that discovers and develops integrin-based treatments. Its primary focus is on developing therapies for solid tumors by blocking integrin-mediated activation of transforming growth factor-β (TGF-β). The company uses its knowledge of integrin biology, medicinal chemistry, and translational medicine to operate a proprietary drug discovery platform. Its wholly owned lead product candidate, PLN-101095, is an oral, small molecule that selectively inhibits both αvβ8 and αvβ1 integrins. This candidate is being developed to treat solid tumors. In 2025, the company reported positive data from a Phase 1 open-label dose-escalation trial of PLN-101095. This trial evaluated PLN-101095 as a standalone treatment and in combination with the immunotherapy pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. The company is also exploring its drug discovery platform, which includes a proprietary library of over 15,000 integrin binding molecules, with a focus on integrin-based target-mediated drug delivery. PLN-101095 targets the TGF-β activating integrins αvβ8 and αvβ1, which are elevated in certain tumors, aiming to make tumors more responsive to checkpoint inhibitors. In March 2025 and December 2025, the company announced positive data from a Phase 1 open label dose-escalation trial of PLN-101095.